Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
AvenCell Therapeutics, Inc.
University of Chicago
Allogene Therapeutics
Genmab
Genmab
National Institutes of Health Clinical Center (CC)
Medical University of South Carolina
Ossium Health, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Essen Biotech
Dana-Farber Cancer Institute
AstraZeneca
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
ARCE Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
M.D. Anderson Cancer Center
Chinese PLA General Hospital
Indapta Therapeutics, INC.
M.D. Anderson Cancer Center
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Instituto Nacional de Cancer, Brazil
Affiliated Hospital to Academy of Military Medical Sciences
Hoffmann-La Roche
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Celgene
University Hospital Heidelberg
Columbia University
Roswell Park Cancer Institute
Indiana University